A phase I open-label, non-randomized study (NCT03618381) is currently evaluating the safety and efficacy of EGFR-targeting CAR-T cells in patients with advanced solid tumors, including esophageal cancer and gastric cancer in children and young adults at Seattle Children's Hospital. Here, EGFR is linked to gastric cancer.